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Objectives: To evaluate rapid molecular approaches for the detection of pyrazinamide (PZA) and ofloxacin 
resistance, by screening 100 known drug-resistant Mycobacterium tuberculosis isolates. 
Methods: Mycobacterium tuberculosis isolates were tested for phenotypic resistance to pyrazinamide and ofloxacin 
using the BACTEC 460 radiometric method and the E-test, respectively. Mutation screening was done by amplifying 
the pncA, gyrA, and gyrB genes by the polymerase chain reaction (PCR) and direct automated sequencing. 
Results: Twelve isolates were PZA-resistant and 8 of 12 (66.7%) isolates had missense mutations or deletions at the 
pncA gene, suggesting that mutation or deletion at the pncA gene is the major molecular mechanism of PZA 
resistance among the Singaporean isolates. Using the E-test, 48 isolates were resistant to ofloxacin, with minimum 
inhibitory concentrations of 4 ug/mL or higher. No mutations were observed at the quinolone resistance-determining 
region (QRDR) of gyrA in all isolates. At the QRDR of gyrB, mutations were present in 1 of 48 ofloxacin-resistant 
isolates and 0 of 19 ofloxacin-susceptible isolates. 
Conclusions: In Singapore, genotypic analysis of resistance to PZA and ofloxacin is inadequate and should be 
complemented by conventional methods. 
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Pyrazinamide (PZA), an analogue of nicotinamide, is 
an important antituberculous drug. It is used together 
with isoniazid and rifampicin for the current short 
course (6 month) chemotherapy of Mycobacterium 
tuberculosis (MTB) infecti0n.l Owing to the emer- 
gence of multidrug-resistant tuberculosis, fluoro- 
quinolones, including ofloxacin, are increasingly used 
for treatment of tuberculosis.2 
In vitro susceptibility testing for PZA and ofloxacin 
have not been routinely available in Singapore and the 
region. The goals of this study were to determine the 
incidence of PZA and ofloxacin resistance among drug- 
resistant MTB isolates from Singapore and to determine 
the feasibility of rapid susceptibility testing by molecular 
methods. One hundred clinical isolates of MTB, known 
to be drug-resistant to at least one first-line antitubercu- 
lous drug, were screened for susceptibility to pyrazina- 
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mide, using the BACTEC 460 radiometric method, and 
for susceptibility to ofloxacin using the E-test. 
To investigate the molecular mechanisms for PZA 
resistance, the authors sequenced the entire pncA gene 
in both PZA-resistant and PZA-susceptible isolates. The 
pncA gene encodes the bacterial enzyme pyrazin- 
amidase (PZase), which converts PZA to bactericidal 
pyrazinoic acid, and loss of PZase activity has been 
correlated with pncA mutations and PZA resistance.36 
Currently, the only known target of fluoroquino- 
lones in mycobacteria is the DNA gyrase, a tetrameric 
protein composed of two A subunits and two B sub- 
units.7-10 Mycobacterial resistance to quinolones has 
been associated with mutations in the quinolone 
resistance-determining regions (QRDR) of gyrA at 
positions 90, 91, and 94 (M. tubercdosis numbering 
system).7-10 The authors sequenced the QRDR regions 
of gyrA and gyrB in clinical isolates of MTB from 
Singapore. 
MATERIALS AND METHODS 
Drug susceptibility testing 
One hundred consecutive Singaporean clinical isolates 
of MTB, known to be resistant to at least one anti- 
tuberculous drug (isoniazid, rifampicin, streptomycin, 
ethambutol) were collected from the Central Tubercu- 
losis Laboratory, Department of Pathology, Singapore 
General Hospital, and have previously been described.ll 
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Clinical information about the subjects has been 
previously published. l2 Of these 100 isolates, 53 were 
resistant to one drug, and the remaining isolates were 
resistant to two or more drugs. These were evaluated 
for phenotypic resistance to pyrazinamide using the 
BACTEC 460 radiometric method (Becton Dickinson, 
Towson, MD), with pyrazinamide at 100 ug/mL. For 
phenotypic resistance to ofloxacin, the E-test was used 
according to the manufacturer’s instructions (AB 
Biodisk, Solna, Sweden). 
DNA extraction 
Table 1. Genetic alterations of the pncA gene in pyrazinamide- 
resistant clinical isolates of mycobacterium tuberculosis 
Codon 
Amino acid Number of 
change Mutation(s) isolates (n= 12) 
10 Gln+Pro CAGXCG 1 
17 Gly4er GGC*AGC 1 
63 Asp-Ala GAC+GCC 1 
97 Gly+Asp GGT+GAT 1 
100 and C deletion 1 
180 Val-+Ala GTC+GCC 
139 Val+Gly GTG+GGG 1 
133-187 - 163bp deletion 1 
1-118 No product for pncA1 1 
No mutations 4 
DNA was extracted from bacterial colonies grown on 
Lowenstein-Jensen slants by first, heat inactivating the 
bacteria at 80°C for 20 minutes, followed by digestion 
with lysozyme and proteinase K. The nucleic acids were 
precipitated with isopropanol, and the nucleic acid pellet 
was resuspended in tris-EDTA (TE) buffer. 
Polymerase chain reaction 
Purified DNA was amplified in a 50-uL polymerase chain 
reaction (PCR) mixture containing 50 mM KCl, 10 mM 
Tris-HCl (pH 9.0 at 25”C), 0.1% Triton X-100, 1.5 mM 
MgC12,lOO uM of each dNTP, 0.25 mM of each primer, 
and 1.25 U of Taq DNA polymerase (Promega, Madison, 
USA). 
PZA-susceptible, and the status of one isolate could 
not be determined as no growth in culture media was 
observed despite several attempts. All 12 PZA-resistant 
isolates and 20 PZA-susceptible isolates were screened 
for mutations at the pncA gene, by amplifying two 
overlapping fragments encompassing the entire pncA 
gene. The PCR products were directly sequenced using 
automated sequencing. Of the 12 PZA-resistant isolates, 
amino acid-altering mutations in pncA were identified 
in six isolates and deletions were identified in two 
isolates (Table 1). No deletions or amino acid-altering 
mutations were detected in any of the 20 PZA- 
susceptible isolates. 
For mutation analysis of the entire pncA gene, 
oligonucleotide primers were designed from the 
complementary sequence of the pncA gene (GenBank 
Accession No. AL021899). Two overlapping fragments 
of 391 bp (nucleotide number 27578-27188) and 313 bp 
(nucleotide number 27251-26939) were amplified. 
Primers for the first fragment were 5’CAAAC- 
TGCCCGGGCAGTCGC3’ (pncAF1) and S’TCAGC- 
AGTGGCGTGCCGTTC3’ (pncAR1) and the primers 
for the second fragment were 5’GGTGCCTACAC- 
CGGAGCGTA3’ (pncAF2) and S’TCCACCGCCGC- 
CAACAGTIC3’ (pncAR2). Oligonucleotide primers 
for the amplification of the gyrA and gyrB genes were 
as previously reported.9 The PCR cycling parameters 
were 94°C for 3 minutes, followed by 25 cycles at 94°C 
for 1 minute, 55°C (pncAl,pncA2, gyrA) or 60°C (gyrB) 
for 1 minute and 72°C for 1 minute. Final extension was 
at 72°C for 5 minutes. 
The minimum inhibitory concentration (MIC) for 
ofloxacin was determined using the E-test in the 100 
clinical isolates of MTB (Table 2). Forty-eight isolates 
had MICs of 4 yg/mL or more and were considered 
resistant. 
The QRDR region of the gyrA gene was sequenced 
for all 100 isolates, with no mutations detected. 
The QRDR of the gyrB gene was sequenced for 48 
ofloxacin-resistant isolates for which the ofloxacin 
MIC was 4 ug/mL or more, and in 24 of 52 ofloxacin- 
susceptible isolates with ofloxacin MICs of less than 
4 ug/ml. A mutation at codon 505 (GAC+GCC) was 
observed in one isolate with ofloxacin MIC of more than 
32 ug/mL. No other mutations were observed. 
DISCUSSION 
Previous studies on PZA-resistant clinical isolates of 
MTB have detected mutations within the pncA gene at 
DNA sequencing 
The PCR products were purified (Wizard PCR Table 2. Ofloxacin minimum inhibitory concentrations (MICs) 
purification kit, Promega, Madison, WI, USA) and of 100 clinical isolates of Mycobacterium tuberculosis 
sequenced using the Applied Biosystems automatic DNA Number of isolates 
sequencer (model 377). 
Ofloxacin MIC @g/ml) 
<3 47 
3 5 
RESULTS 4 11 
6 2 
Of 100 Singaporean drug-resistant MTB isolates, 12 I6 1 
isolates were confirmed to be PZA-resistant, 87 were >32 34 
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frequencies of between 72% to 97% .46 These mutations 
were observed throughout the entire length of the gene 
and included upstream mutations, missense changes, 
nucleotide insertions and deletions, and termination 
mutations. To characterize the molecular changes of 
pncA among local isolates from Singapore, the entire 
pncA gene was amplified and directly sequenced. 
Missense mutations and deletions were present in 67% 
of the Singaporean PZA-resistant clinical isolates of 
MTB, and these molecular changes spanned the entire 
pncA gene. Interestingly, none of the mutations or 
deletions detected in the Singaporean isolates have been 
observed in other studies.4-6 One mutation at codon 63 
(Asp-Ala) resulted in a different amino acid change 
than that previously reported by Scorpio and Zhang 
(Asp+His).3 
A common problem of current PZA susceptibility 
testing is the occurrence of false resistance, in which the 
isolates are susceptible upon retesting. Scorpio and 
colleagues reported that four PZA-resistant strains, as 
determined by the BACTEC method, were in fact 
susceptible.4 Differences in the susceptibility testing 
methods as well as the cutoff concentrations of pyra- 
zinamide, ranging from 25 ug/mL to 400 ug/mL may 
contribute to the differences in the frequencies of 
mutation at pncA. Sreevatsan and co-workers reported 
a frequency of pncA mutations in only 72% of their 
isolates5 similar to the frequency noted in the current 
study. Their isolates were tested for PZA susceptibility 
by the BACTEC method or the conventional propor- 
tion method with PZA concentration of 25 ug/mL. 
Hirano and colleagues detected mutations in pncA in 
97 % of isolates with MICs of PZA at pH 6.0 of over 400 
ug/mL.6 No mutations were present in three isolates 
with MICs of 100 ug/mL but only in five with MICs 
greater than 500 ug/mL.3 Hence, mutations in pncA may 
be correlated with isolates with higher MICs, and 
isolates with lower MICs may be falsely resistant. 
Mutation or deletion at the pncA gene appears to 
be the major molecular mechanism of PZA resistance 
among the Singaporean isolates. However, a separate 
mechanism for PZA resistance may exist for the remain- 
ing one third of the PZA-resistant isolates for which no 
mutations or deletions were observed. 
Mutations at the QRDR of the gyrA gene at codons 
90,91, or 94 have been identified in 85% and 100% of 
fluoroquinolone (FQ)-resistant isolates of MTB.7,8 In 
contrast to these studies, no mutations at gyrA were 
detected in any of the Singaporean isolates. This suggests 
that alternative gene targets and mechanisms, such 
as impermeability attributable to alterations in outer 
membrane proteins and lowered levels of intracellular 
drug concentrations caused by energy-dependent efflux 
pumps may play a role in these isolates.13-l6 
A low incidence of ofloxacin resistance has been 
reported by other investigators from Thailand (1.8%) 
and Taiwan (1.5 % ) , 17,18 which is similar to the incidence 
detected genotypically in the present study. The high 
incidence of ofloxacin resistance (48%) in Singapore, 
detected phenotypically using the E-test, was unexpected 
as ofloxacin has been shown to be effective in the 
treatment of patients with multidrug-resistant tubercu- 
losis (MDR-TB) in countries in the region.19,20 The in 
vitro phenotypic testing was repeated on numerous 
occasions using different batches of E-test strips, with 
similar results. Further independent studies using the E- 
test for susceptibility testing of ofloxacin in MTB 
isolates is recommended. 
This present study emphasizes the need for 
detailed genotypic analysis of “local” clinical isolates 
before strategies for rapid susceptibility determination 
are used, because mutations at a gene target may differ 
from one geographic region to another. The authors’ 
previous report on genotypic analysis of isoniazid 
resistance highlighted differences in the prevalence 
of specific genotypes between different geographic 
regions.lr In that study, the targeted approach of 
analysis of the codon 315 region of the k&G gene and 
the promoter regions of inhA and oxyR-ahpC detected 
mutations in only 62.5% of isoniazid-resistant strains 
from Singapore, in contrast to 87% in Spain.21 A similar 
situation was also observed here for PZA. Finally, we 
report discrepancy between the commercially available 
phenotypic E-test and genotypic analysis of ofloxacin 
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